Molecular Imaging 2017

Phase I/II trials

Vascular Response Markers

 DCE-MRI or CT used in >100 early phase trials of anti- vascular drugs  ΔK trans & IAUC 60 :  Proof-of-principle  Optimum drug dose & schedule e.g. cediranib*, brivanib**

O’Connor JP et al. Nat Rev Clin Oncol 2012; 9: 167-77 *Drevs J et al. J Clin Oncol 2007; 25: 3045-54; **Jonker et al. Ann Oncol 2011; 22: 1413-9